Are CSL shares a buy after the biotech's FY25 forecasts?

MotleyFool11-11

If you've been tracking CSL Limited (ASX: CSL) shares lately, you might be wondering whether now is the right time to invest in this Australian biotech heavyweight. The share price is hovering around...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482560249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482560249","market":"us","top_or_hot":-1,"title":"Are CSL shares a buy after the biotech's FY25 forecasts?","media":"MotleyFool","content":"<div>\n<p>If you've been tracking CSL Limited (ASX: CSL) shares lately, you might be wondering whether now is the right time to invest in this Australian biotech heavyweight.  The share price is hovering around...</p>\n\n<a href=\"https://www.fool.com.au/2024/11/11/are-csl-shares-a-buy-after-the-biotechs-fy25-forecasts/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are CSL shares a buy after the biotech's FY25 forecasts?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre CSL shares a buy after the biotech's FY25 forecasts?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2024/11/11/are-csl-shares-a-buy-after-the-biotechs-fy25-forecasts/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you've been tracking CSL Limited (ASX: CSL) shares lately, you might be wondering whether now is the right time to invest in this Australian biotech heavyweight.  The share price is hovering around...</p>\n\n<a href=\"https://www.fool.com.au/2024/11/11/are-csl-shares-a-buy-after-the-biotechs-fy25-forecasts/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGM","symbol_name":"联邦农业抵押贷款公司","start_time":0,"source_url":"https://www.fool.com.au/2024/11/11/are-csl-shares-a-buy-after-the-biotechs-fy25-forecasts/","article_id":"2482560249","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482560249","pubTimestamp":1731290600,"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"If you've been tracking CSL Limited (ASX: CSL) shares lately, you might be wondering whether now is the right time to invest in this Australian biotech heavyweight.  The share price is hovering around","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGM":"联邦农业抵押贷款公司","CSL":"卡莱尔伙伴","BK7501":"新冠治疗股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4195":"互助储蓄与抵押信贷金融服务","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","CSL.AU":"CSL LIMITED","BK7508":"医药生物股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4086":"建筑产品","BK7067":"生物科技","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","AGM.AU":"Australian Governance and Ethical Index Fund","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4229":"商业和住宅抵押贷款融资","BK7511":"ESG概念"},"translate_title":"在生物技术公司发布2025财年预测后，CSL股票是否值得买入？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGM":1,"AGM.AU":1,"CSL":1,"CSL.AU":1},"content_text":"If you've been tracking CSL Limited (ASX: CSL) shares lately, you might be wondering whether now is the right time to invest in this Australian biotech heavyweight.  The share price is hovering around $285.72 at the time of writing, and it is trading near its lowest levels in three months. However, the biotech giant recently reaffirmed its forecasts for FY25, adding a potential thrust of optimism for those seeking clarity on the company's direction.  Let's see if the experts say whether CSL deserves a spot in your portfolio.  CSL shares offer value after FY25 guidance affirmed CSL reaffirmed its guidance for FY25 in its annual general meeting (AGM) in October. In it, management projected CSL will hit net profit after tax and amortisation (NPATA) between US$3.2 billion and US$3.3 billion.  This represents a constant currency growth of 10% to 13%. It sees this from revenue growth of 5% to 7% for the year when looking at USD only. According to Ord Minnett, fluctuating exchange rates will cause a US$50 million currency headwind for the biotech's FY25 numbers, but this should be a minor blip. The broker is bullish on CSL, rating it a buy, according to The Bull. Analyst Tony Paterno notes:  CSL is a global biotechnology company. CSL recently reaffirmed fiscal year 2025 guidance. It's forecasting net profit after tax and amortization (NPATA) to range between $US3.2 billion and $US3.3 billion, reflecting constant currency growth of between 10% and 13%… …According to our analysis, this headwind implies consensus NPATA of $US2.27 billion, which is 0.6 per cent above the top end of guidance.  Brokers are bullish on aggregate It's not just Ord Minnett on the bullish gravy train for the biotech. Several top brokers are bullish on CSL shares, and for good reason.  Bell Potter believes now might be a good time to add this biotech leader to your portfolio. In a client note this week, the broker highlights that CSL is entering a margin recovery phase, which could drive above-market earnings growth in the coming years. It says CSL \"presents an attractive buying opportunity\" as it enters this margin recovery phase.  Bell also notes that CSL trades at a discount to its 10-year average of 31 times forward earnings and that it \"will continue to deleverage the balance sheet over the next few years\".  Meanwhile, Citi analysts share the enthusiasm, retaining the bank's buy rating and setting a price target of $345 on CSL shares. Each of these brokers joins the consensus view on CSL, which says it is a buy, according to CommSec. No analysts recommend selling CSL shares at this moment.  Foolish takeout CSL shares have long been a darling of the ASX, boasting a stellar track record on the chart and in plasma therapies. Experts continue to see further upside in the biotech stock, more so with its reaffirmed FY25 numbers.  The stock is up 13% in the last 12 months despite remaining flat for the year to date.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482560249"}